Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic up-front payment to Abbott

This article was originally published in The Gray Sheet

Executive Summary

First-quarter (ending July 31) one-time charge of $40-45 mil. will be taken as part of the licensing agreement for Abbott's rapamycin analogue ABT-578 and phosphorylcholine polymer coating technology with Medtronic's over-the-wire and rapid-exchange stent delivery systems outside the U.S., Medtronic tells investors June 24. The firms announced the deal May 9 (1"The Gray Sheet" May 13, 2002, p. 8)...

You may also be interested in...

Medtronic Licensing Deal With Abbott Is Hawkins’ First Test: Results Pending

William Hawkins' initial stamp on Medtronic's struggling AVE vascular business includes a licensing deal with Abbott Laboratories for a drug-eluting stent compound and an unrelated restructuring of the operating unit, both announced May 9

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.

Rapid Biopharma Response To COVID-19 Enabled By Decades Of R&D Investment, Firms Say

Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts